Scarica l'app Stockscreener
2.50
3.10%
-0.08
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AYTU Giù?
Forum
Previsione
Frazionamento azionario
Aytu Biopharma Inc Borsa (AYTU) Ultime notizie
Analysts Expect Breakeven For Aytu BioPharma, Inc. (NASDAQ:AYTU) Before Long - Yahoo Finance
Comparing Sanofi (NASDAQ:SNY) & Aytu BioPharma (NASDAQ:AYTU) - Defense World
Alaska Air clears hurdle in proposed merger with Hawaiian Airlines - Head Topics
Aytu BioPharma, Inc. (NASDAQ:AYTU) Short Interest Update - Defense World
Aytu BioPharma (NASDAQ:AYTU) Share Price Crosses Below 50 Day Moving Average of $2.77 - Defense World
Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024 - AccessWire
Aytu BioPharma sells consumer health unit to focus on Rx products - Investing.com India
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations - AccessWire
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations - StockTitan
Aytu BioPharma (NASDAQ:AYTU) & SIGA Technologies (NASDAQ:SIGA) Critical Analysis - American Banking and Market News
Aytu BioPharma (NASDAQ:AYTU) vs. SIGA Technologies (NASDAQ:SIGA) Financial Survey - Defense World
Aytu BioPharma (NASDAQ:AYTU) Share Price Crosses Below 50 Day Moving Average of $2.89 - Defense World
Aytu BioPharma (NASDAQ:AYTU) Share Price Passes Below 50 Day Moving Average of $2.95 - Defense World
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.
Aytu BioPharma Inc. (AYTU) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo News Australia
Aytu BioPharma Shareholders Approve All Proposals at Annual Meeting - Investing.com India
Aytu BioPharma Shareholders Approve All Proposals at Annual Meeting By Investing.com - Investing.com Australia
Aytu BioPharma Shareholders Approve All Proposals at Annual Meeting By Investing.com - Investing.com South Africa
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Evofem Biosciences revises preferred stock terms By Investing.com - Investing.com
Aytu BioPharma Shareholders Approve All Proposals at Annual Meeting By Investing.com - Investing.com UK
Analyst boosts PB Fintech stock target on strong 1Q operational trends By Investing.com - Investing.com UK
US$5.50: That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After Its Latest Results - Yahoo New Zealand News
Aytu BioPharma Shareholders Approve All Proposals at Annual Meeting - Investing.com
Massimo Group showcases new line at equipment show By Investing.com - Investing.com India
It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year - Simply Wall St
It's Unlikely That The CEO Of Aytu BioPharma, Inc. (NASDAQ:AYTU) Will See A Huge Pay Rise This Year - Yahoo Finance
Aytu Biopharma announces paydown and refinancing of term loan (NASDAQ:AYTU) - Seeking Alpha
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms - StockTitan
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms - AccessWire
Aytu BioPharma (NASDAQ:AYTU) Stock Crosses Below 50 Day Moving Average of $3.03 - Defense World
Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden - Simply Wall St
Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Expected To Breakeven In The Medium-Term - Yahoo Canada Shine On
Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 - Yahoo Canada Finance
Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 - Yahoo Finance
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Aytu BioPharma sees revenue growth, shifts focus to ADHD - Investing.com India
Earnings call: Aytu BioPharma sees revenue growth, shifts focus to ADHD - Investing.com
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference - Yahoo Finance UK
AYTU Stock Earnings: Aytu BioPharma Beats EPS, Beats Revenue for Q3 2024 - MSN
Aytu BioScience up 5% as quarterly results beat on both lines - Seeking Alpha
Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results15.05.2024 - wallstreet:online
Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results - AccessWire
Attention Deficit Hyperactivity Disorder (ADHD) Treatment Market - openPR
Bears are Losing Control Over Aytu BioPharma Inc. (AYTU), Here's Why It's a 'Buy' Now - Yahoo Singapore News
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024 - Yahoo Finance
Aytu BioPharma Inc. (AYTU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo News UK
3 Cheap Stocks to Buy Now - Wealth Daily
Market Sentiment Around Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) - Simply Wall St
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024 - Investing.com India
US$8.00That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results - Simply Wall St
Earnings call: Aytu BioPharma achieves first positive operating income - Investing.com India
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter - Yahoo Finance
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024 - Yahoo Finance
Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet? - Simply Wall St
When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Become Profitable? - Yahoo Finance
Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023 - Yahoo Finance
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call Transcript - Yahoo Finance
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results - wallstreet:online
Aytu BioPharma's Earnings: A Preview - Quantisnow
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year - Yahoo Finance
Premature Ejaculation (PE) Treatment Market size to grow by USD 1.45 billion from 2023-2028| A. Menarini Industrie ... - The Malaysian Reserve
Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement - Yahoo Finance
Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023 - Yahoo Finance
There's No Escaping Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Muted Revenues - Yahoo Finance
1.01%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):